Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a publicly traded Healthcare sector company. As of October 24, 2026, ARTV trades at $6.15 with a market cap of $303.12M and a P/E ratio of -2.09. ARTV moved -1.05% today. Year to date, ARTV is +47.48%; over the trailing twelve months it is +27.07%. Its 52-week range spans $1.47 to $14.53. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces ARTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Artiva posts updated Phase 2a AlloNK plus rituximab data in refractory rheumatoid arthritis at ACR 2026: Artiva Biotherapeutics plans to present updated Phase 2a data for AlloNK plus rituximab at ACR Convergence in November, covering at least 20 refractory rheumatoid arthritis patients with six months of follow-up.
| Metric | Value |
|---|---|
| Price | $6.15 |
| Market Cap | $303.12M |
| P/E Ratio | -2.09 |
| EPS | $-3.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.53 |
| 52-Week Low | $1.47 |
| Volume | 267.99K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-83.86M |
| Gross Margin | 0.00% |
3 analysts cover ARTV: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.